Clinical Evolution and Risk Factors of Hospitalized Patients with COVID-19, Haiti, March-June 2020
Keywords:
Coronavirus, COVID-19, comorbidity, risk factors, clinical evolution, signs and symptoms, recovery, death severityAbstract
In December 2019, a coronavirus epidemic emerged in China. Within months, the epidemic was considered a public health emergency of international concern. In Haiti, the first laboratory-confirmed cases of COVID-19 were reported on March 19, 2020, in a context where there was some limitations of knowledge on the modes of transmission, the severity, the clinical characteristics and the risk factors of the disease. This study has made it possible to characterize the epidemic and investigate the associations between the risk factors, co morbidities, and clinical evolution of the disease.
To develop the epidemiological and clinical profile of patients with COVID-19 in Haiti, data were collected from the clinical records of patients hospitalized for COVID-19 from March 16 to June 16, 2020, in 22 healthcare facilities. Univariate, bivariate, and logistic regression model analyses were performed to describe and explore the risk factors, comorbidities, and treatments associated with patients’ clinical evolution. Statistical significance was determined using a 95% confidence interval or p-value of ?0.05. Diabetes and high blood pressure were the main comorbidities that had a statistically significant association with the severe form of the disease and the occurrence of death. The likelihood of dying increased with age, and patients in the severe form were almost four times more likely to die. The administration of ceftriaxone to patients was significantly related to recovery from the disease. Diabetes, high blood pressure, and age were the major risk factors for the severity and mortality of people infected with COVID19. Ceftriaxone administration was protective against recovery.
References
. Coronavirus disease (COVID-19) [Internet]. [cité 12 mars 2022]. Disponible sur: https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-covid-19
. Noronha KVM de S, Guedes GR, Turra CM, Andrade MV, Botega L, Nogueira D, et al. The COVID-19 pandemic in Brazil: analysis of supply and demand of hospital and ICU beds and mechanical ventilators under different scenarios. Cad Saude Publica. 2020;36(6):e00115320.
. protocolo_atendimento_coronavirus_v12.pdf [Internet]. [cité 12 mars 2022]. Disponible sur: https://www.hcor.com.br/wp-content/uploads/2020/06/protocolo_atendimento_coronavirus_v12.pdf
. Weiss P, Murdoch DR. Clinical course and mortality risk of severe COVID-19. Lancet. 28 mars 2020;395(10229):1014?5.
. Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 6 juin 2020;395(10239):1763?70.
. Unity Studies: Early Investigation Protocols [Internet]. [cité 14 mars 2022]. Disponible sur: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/early-investigations
. Serafim RB, Póvoa P, Souza-Dantas V, Kalil AC, Salluh JIF. Clinical course and outcomes of critically ill patients with COVID-19 infection: a systematic review. Clin Microbiol Infect. janv 2021;27(1):47?54.
. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 15 févr 2020;395(10223):507?13.
. Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020;395(10239):1763?70.
. Weiss P, Murdoch DR. Clinical course and mortality risk of severe COVID-19. Lancet. 2020;395(10229):1014?5.
. Wang D, Yin Y, Hu C, Liu X, Zhang X, Zhou S, et al. Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan, China. Crit Care. 30 2020;24(1):188.
. HCSP. Coronavirus SARS-CoV-2?: recommandations thérapeutiques [Internet]. Rapport de l’HCSP. Paris: Haut Conseil de la Santé Publique; 2020 mars [cité 14 sept 2020]. Disponible sur: https://www.hcsp.fr/explore.cgi/avisrapportsdomaine?clefr=785
. WHO-nCoV-Clinical-2020.3-fre.pdf [Internet]. [cité 14 sept 2020]. Disponible sur: https://apps.who.int/iris/bitstream/handle/10665/330943/WHO-nCoV-Clinical-2020.3-fre.pdf
. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054?62.
. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. juill 2020;146(1):110?8.
. Al-Salameh A, Lanoix JP, Bennis Y, Andrejak C, Brochot E, Deschasse G, et al. Characteristics and outcomes of COVID-19 in hospitalized patients with and without diabetes. Diabetes Metab Res Rev. mars 2021;37(3):e3388.
. Elezkurtaj S, Greuel S, Ihlow J, Michaelis EG, Bischoff P, Kunze CA, et al. Causes of death and comorbidities in hospitalized patients with COVID-19. Sci Rep. 19 févr 2021;11(1):4263.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 International Journal of Sciences: Basic and Applied Research (IJSBAR)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors who submit papers with this journal agree to the following terms.